Cargando…
Sulindac activates NF-κB signaling in colon cancer cells
BACKGROUND: The non-steroidal anti-inflammatory drug (NSAID) sulindac has shown efficacy in preventing colorectal cancer. This potent anti-tumorigenic effect is mediated through multiple cellular pathways but is also accompanied by gastrointestinal side effects, such as colon inflammation. We have r...
Autores principales: | Mladenova, Dessislava, Pangon, Laurent, Currey, Nicola, Ng, Irvin, Musgrove, Elizabeth A, Grey, Shane T, Kohonen-Corish, Maija RJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896984/ https://www.ncbi.nlm.nih.gov/pubmed/24083678 http://dx.doi.org/10.1186/1478-811X-11-73 |
Ejemplares similares
-
HIF1α deficiency reduces inflammation in a mouse model of proximal colon cancer
por: Mladenova, Dessislava N., et al.
Publicado: (2015) -
Microsatellite Instability in Mouse Models of Colorectal Cancer
por: Currey, Nicola, et al.
Publicado: (2018) -
Proteogenomic Analysis Identifies a Novel Human SHANK3 Isoform
por: Benthani, Fahad, et al.
Publicado: (2015) -
MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib
por: Jahan, Zeenat, et al.
Publicado: (2022) -
Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats
por: Madka, Venkateshwar, et al.
Publicado: (2023)